Predict your next investment

Corporation
HEALTHCARE | Biotechnology
viropharma.com

See what CB Insights has to offer

Competitors

16

Business Relationships

5

Service Providers

2

ViroPharma Competitors & Alternatives

16 Competitors

ViroPharma has 16 competitors. ViroPharma's competitors are Longevica, Array Biopharma, Aerie Pharmaceuticals, BIND Therapeutics, Idenix Pharmaceuticals and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

11/24/2021

Unattributed VC

$3M

New Jersey

7/30/2019

Acq - P2P

$32.81M

Colorado

6/1/2018

PIPE

$71M

New Jersey

7/28/2016

Asset Sale

$127.98M

Massachusetts

8/5/2014

Acq - P2P

$68.91M

Massachusetts

8/13/2010

Zystor Therapeutics

Acquired

$8.5M

Wisconsin

10/31/2009

RevDia

Series C

Florida

8/4/2009

Critical Biologics

Debt

$9.81M

Massachusetts

7/20/2009

American Stem Cell

Grant

$2.5M

Texas

11/27/2006

Newron Pharmaceuticals

IPO

$36M

Italy

Latest Funding

11/24/2021

7/30/2019

6/1/2018

7/28/2016

8/5/2014

8/13/2010

10/31/2009

8/4/2009

7/20/2009

11/27/2006

Companies

Zystor Therapeutics

RevDia

Critical Biologics

American Stem Cell

Newron Pharmaceuticals

Investment Stage

Unattributed VC

Acq - P2P

PIPE

Asset Sale

Acq - P2P

Acquired

Series C

Debt

Grant

IPO

Total Funding

$3M

$32.81M

$71M

$127.98M

$68.91M

$8.5M

$9.81M

$2.5M

$36M

Mosaic

Location

New Jersey

Colorado

New Jersey

Massachusetts

Massachusetts

Wisconsin

Florida

Massachusetts

Texas

Italy

ViroPharma Service Providers

2 Service Providers

ViroPharma has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Accounting Firm

Auditor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Provider Type

Accounting Firm

Subscribe to see more

Service Type

Auditor

Subscribe to see more

Partnership data by VentureSource

ViroPharma Partners & Customers

5 Partners and customers

ViroPharma has 5 strategic partners and customers. ViroPharma recently partnered with Intellect Neurosciences on September 9, 2011.

Date

Type

Business Partner

Country

News Snippet

Sources

9/30/2011

Licensor

Intellect Neurosciences

United States

Intellect to Receive Upfront Payment of $6.5 Million, Potential Milestone Payments of $120 Million, and Royalty on Future Sales. Intellect Neurosciences and ViroPharma Announce $126.5 Million Global Licensing Agreement to Develop and Commercialize OX1 for Friedreich's Ataxia and Other Neurodegenerative Diseases :: Intellect Neurosciences, Inc

The universities , which own certain patents in relation to OX1 , are entitled to a portion of revenues received by Intellect Neurosciences , Inc. from any sale or license of OX1 pursuant to an exclusive license agreement between Intellect Neurosciences , Inc. and the universities .

4

3/17/2011

Partner

Medidata Solutions

United States

Subscribe to see more

Subscribe to see more

10

1/11/2010

Partner

Sanquin Blood Supply Foundation

Subscribe to see more

Subscribe to see more

10

12/11/2006

Vendor

Medidata Solutions

United States

Subscribe to see more

Subscribe to see more

10

1/7/2005

Licensee

Schering-Plough

United States

Subscribe to see more

Subscribe to see more

10

Date

9/30/2011

3/17/2011

1/11/2010

12/11/2006

1/7/2005

Type

Licensor

Partner

Partner

Vendor

Licensee

Business Partner

Intellect Neurosciences

Medidata Solutions

Sanquin Blood Supply Foundation

Medidata Solutions

Schering-Plough

Country

United States

United States

United States

United States

News Snippet

Intellect to Receive Upfront Payment of $6.5 Million, Potential Milestone Payments of $120 Million, and Royalty on Future Sales. Intellect Neurosciences and ViroPharma Announce $126.5 Million Global Licensing Agreement to Develop and Commercialize OX1 for Friedreich's Ataxia and Other Neurodegenerative Diseases :: Intellect Neurosciences, Inc

The universities , which own certain patents in relation to OX1 , are entitled to a portion of revenues received by Intellect Neurosciences , Inc. from any sale or license of OX1 pursuant to an exclusive license agreement between Intellect Neurosciences , Inc. and the universities .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.